No abstract

BackgroundOver 300,000 people in the United States are infected with Trypanosoma cruzi, the parasite that causes Chagas disease. Less than 1% of those people have received antitrypanosomal therapy. We report findings of an ongoing project to address Chagas disease in East Boston, including the epidemiology and cascade of care for this disease.MethodsProviders at the East Boston Neighborhood Health Center were offered continuing medical education sessions on Chagas disease by the Strong Hearts project. One-time screening for Chagas disease is recommended for all patients <50 years old who had lived in Mexico, South or Central America for ≥6 months at the provider’s discretion. Screening is performed by a commercial laboratory using the Hemagen ELISA; confirmatory testing is performed at CDC. Patients with confirmed positive serology are referred to the Center for Infectious Diseases (ID) at Boston Medical Center for evaluation and treatment. We compared the prevalence of Chagas disease by age, sex and national origin. We then used a conditional numerator and fixed denominator to construct the cascade of care, with the stages defined as referred to ID care, evaluation in ID, initiation of treatment and completion of antitrypanosomal therapy. We used chi-squared tests to compare proportions.ResultsFrom March 21, 2017 to April 17, 2019, 5,125 patients were screened. 50 (0.97%) were confirmed to have T. cruzi infection, among them 3 pregnant women. There were no differences in the prevalence of T. cruzi infection by sex (M = 22/1870 [1.18%], F = 28/3305 [0.85%], P = 0.245) but prevalence increased from 0/190 (0%) in those <20 years old to 11/1083 (1.02%) in 40–49 year olds (P = 0.001). The 3 infants of infected mothers were screened. The cascade of care for Strong Hearts is displayed in Figure 1.ConclusionChagas disease prevalence in at-risk communities in Boston is substantial. 20% of patients with T. cruzi infection identified in this program have completed treatment to date. Most infected patients were referred for evaluation, but substantial drop-off occurred at each of the next 3 steps of the cascade. Confronting barriers at each of these steps is a crucial component of efforts to address this neglected disease. Disclosures All authors: No reported disclosures.

Background In the United States, diabetes mellitus (DM) is among the most common chronic diseases, with approximately 34.2 million people affected. DM has also emerged as a commonly reported risk factor among people hospitalized with coronavirus disease 2019 (COVID-19). In this study, we sought to evaluate whether people with DM who are hospitalized with COVID-19 were more likely to experience poor early outcomes and whether this association remained after adjustment for obesity status. Methods We analyzed data from the Massachusetts General Hospital (MGH) COVID-19 Data Registry. The sample included 450 people with PCR-confirmed SARS-CoV-2 infection who were hospitalized at MGH between March 11, 2020 and April 30, 2020. The primary outcomes were (1) admission to the intensive care unit (ICU) and (2) need for mechanical ventilation or death, both within 14 days of presentation to care. Data were obtained by manual chart review and via an EMR-associated database. Logistic regression was used to evaluate the relationship between diabetes and these outcomes. All models were adjusted for age, sex, race, BMI category and key comorbidities. Results In this study, 178 (39.6%) of 450 participants had DM and 346 (76.9%) were overweight or obese. People with DM were on average older and had a higher BMI than those without DM. A higher percentage of patients with DM were admitted to the ICU (42.1% vs 29.8%, p=0.007) and required mechanical ventilation or died (46.6% vs 27.7%, p&lt; 0.001), compared with patients without DM (Figure 1). In adjusted models, DM was associated with a greater odds of ICU admission (aOR: 1.58 [95% CI: 1.01–2.46]) and mechanical ventilation or death (2.15 [1.38–3.34). Obesity was associated with a greater odds of ICU admission (2.15 [1.20–3.86]) but not with mechanical ventilation or death (1.52 [0.87–2.67]). Table 1 provides the model results in full. Figure 1. ICU Admission and mechanical ventilation or death within 14-days by diabetes status among 450 people hospitalized with COVID-19 Conclusion Diabetes was associated with poor outcomes within 14-days of presentation to care for COVID-19. These findings remained after adjustment for obesity. Our findings can help guide risk mitigation efforts and patient-centered care decision making for people with DM and obesity, particularly in areas of the US that have a high prevalence of DM and obesity and are in early phases of the SARS-CoV-2 outbreak. Disclosures Sara Jane Cromer, MD, Depuy-Synthes (a Johnson & Johnson company) (Employee) James Meigs, MD, Quest Diagnostics (Other Financial or Material Support, Academic Associate) Deborah Wexler, MD, Novo Nordisk (Other Financial or Material Support, Data Monitoring Committee)